What Are the Best AI Power Stocks?
As the construction of AI infrastructure accelerates, the gap between…
Sell
24
MBIO Quote, Financials, Valuation and Earnings
Last price:
$1.17
Seasonality move
:
-2.69%
Day range:
$1.17 - $1.26
52-week range:
$0.89 - $21.95
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
--
P/B ratio:
0.89x
Volume:
71.5K
Avg. volume:
95.5K
1-year change:
-88.34%
Market cap:
$8.7M
Revenue:
--
EPS (TTM):
-$1.27
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
MBIO
Mustang Bio, Inc.
|
-- | -$8.00 | -- | -89.43% | -- |
|
AGEN
Agenus, Inc.
|
$80.4M | $2.20 | 144.6% | -70.59% | $12.33 |
|
AIM
AIM ImmunoTech
|
-- | -$0.09 | -23.08% | -53.85% | $4.50 |
|
ARMP
Armata Pharmaceuticals, Inc.
|
$1.4M | -$0.42 | 19.84% | -177.23% | $9.00 |
|
CRIS
Curis, Inc.
|
$2.9M | -$0.60 | -2.86% | -65.51% | $14.00 |
|
PLX
Protalix Biotherapeutics, Inc.
|
$17.9M | -- | -7.76% | -- | $11.00 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
MBIO
Mustang Bio, Inc.
|
$1.20 | -- | $8.7M | -- | $0.00 | 0% | -- |
|
AGEN
Agenus, Inc.
|
$3.79 | $12.33 | $128.9M | -- | $0.00 | 0% | 0.96x |
|
AIM
AIM ImmunoTech
|
$0.04 | $4.50 | $2.8M | -- | $0.00 | 0% | 13.27x |
|
ARMP
Armata Pharmaceuticals, Inc.
|
$5.90 | $9.00 | $214.3M | -- | $0.00 | 0% | 48.94x |
|
CRIS
Curis, Inc.
|
$1.16 | $14.00 | $15M | -- | $0.00 | 0% | 1.11x |
|
PLX
Protalix Biotherapeutics, Inc.
|
$1.79 | $11.00 | $144M | 25.76x | $0.00 | 0% | 2.28x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
MBIO
Mustang Bio, Inc.
|
-- | 3.541 | -- | 2.01x |
|
AGEN
Agenus, Inc.
|
510.35% | 4.383 | 285.06% | 0.03x |
|
AIM
AIM ImmunoTech
|
48.41% | 0.745 | 17.25% | 0.71x |
|
ARMP
Armata Pharmaceuticals, Inc.
|
216.44% | 3.715 | 164.57% | 0.11x |
|
CRIS
Curis, Inc.
|
192.35% | 3.282 | 144.76% | 0.62x |
|
PLX
Protalix Biotherapeutics, Inc.
|
13.39% | -1.718 | 4.58% | 2.00x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
MBIO
Mustang Bio, Inc.
|
-- | -$624K | -208.33% | -311.92% | -- | -$818K |
|
AGEN
Agenus, Inc.
|
$26.6M | -$4.9M | -39.69% | -- | -16.08% | -$14.7M |
|
AIM
AIM ImmunoTech
|
$27K | -$4.5M | -219.06% | -256.33% | -9994.29% | -$3.3M |
|
ARMP
Armata Pharmaceuticals, Inc.
|
$789K | -$7.8M | -57.86% | -- | -670.92% | -$4.5M |
|
CRIS
Curis, Inc.
|
$3.1M | -$6.9M | -147.67% | -461.34% | -218.01% | -$5.6M |
|
PLX
Protalix Biotherapeutics, Inc.
|
$9.5M | $2.1M | 10.63% | 12.06% | 11.94% | -$4.2M |
Mustang Bio, Inc. vs. Competitors
-
Which has Higher Returns MBIO or AGEN?
Agenus, Inc. has a net margin of -- compared to Mustang Bio, Inc.'s net margin of -116.82%. Mustang Bio, Inc.'s return on equity of -311.92% beat Agenus, Inc.'s return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital MBIOMustang Bio, Inc.-- -$0.08 $9.8M AGENAgenus, Inc.87.85% $1.94 $60.1M -
What do Analysts Say About MBIO or AGEN?
Mustang Bio, Inc. has a consensus price target of --, signalling upside risk potential of 8268.2%. On the other hand Agenus, Inc. has an analysts' consensus of $12.33 which suggests that it could grow by 225.42%. Given that Mustang Bio, Inc. has higher upside potential than Agenus, Inc., analysts believe Mustang Bio, Inc. is more attractive than Agenus, Inc..
Company Buy Ratings Hold Ratings Sell Ratings MBIOMustang Bio, Inc.0 0 0 AGENAgenus, Inc.2 1 0 -
Is MBIO or AGEN More Risky?
Mustang Bio, Inc. has a beta of 2.086, which suggesting that the stock is 108.57% more volatile than S&P 500. In comparison Agenus, Inc. has a beta of 1.510, suggesting its more volatile than the S&P 500 by 51.01%.
-
Which is a Better Dividend Stock MBIO or AGEN?
Mustang Bio, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Agenus, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Mustang Bio, Inc. pays -- of its earnings as a dividend. Agenus, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios MBIO or AGEN?
Mustang Bio, Inc. quarterly revenues are --, which are smaller than Agenus, Inc. quarterly revenues of $30.2M. Mustang Bio, Inc.'s net income of -$468K is lower than Agenus, Inc.'s net income of $63.9M. Notably, Mustang Bio, Inc.'s price-to-earnings ratio is -- while Agenus, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Mustang Bio, Inc. is -- versus 0.96x for Agenus, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income MBIOMustang Bio, Inc.-- -- -- -$468K AGENAgenus, Inc.0.96x -- $30.2M $63.9M
-
Which has Higher Returns MBIO or AIM?
AIM ImmunoTech has a net margin of -- compared to Mustang Bio, Inc.'s net margin of -10571.43%. Mustang Bio, Inc.'s return on equity of -311.92% beat AIM ImmunoTech's return on equity of -256.33%.
Company Gross Margin Earnings Per Share Invested Capital MBIOMustang Bio, Inc.-- -$0.08 $9.8M AIMAIM ImmunoTech77.14% -$0.06 $5.6M -
What do Analysts Say About MBIO or AIM?
Mustang Bio, Inc. has a consensus price target of --, signalling upside risk potential of 8268.2%. On the other hand AIM ImmunoTech has an analysts' consensus of $4.50 which suggests that it could grow by 11066.25%. Given that AIM ImmunoTech has higher upside potential than Mustang Bio, Inc., analysts believe AIM ImmunoTech is more attractive than Mustang Bio, Inc..
Company Buy Ratings Hold Ratings Sell Ratings MBIOMustang Bio, Inc.0 0 0 AIMAIM ImmunoTech1 0 0 -
Is MBIO or AIM More Risky?
Mustang Bio, Inc. has a beta of 2.086, which suggesting that the stock is 108.57% more volatile than S&P 500. In comparison AIM ImmunoTech has a beta of 0.760, suggesting its less volatile than the S&P 500 by 23.953%.
-
Which is a Better Dividend Stock MBIO or AIM?
Mustang Bio, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. AIM ImmunoTech offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Mustang Bio, Inc. pays -- of its earnings as a dividend. AIM ImmunoTech pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios MBIO or AIM?
Mustang Bio, Inc. quarterly revenues are --, which are smaller than AIM ImmunoTech quarterly revenues of $35K. Mustang Bio, Inc.'s net income of -$468K is higher than AIM ImmunoTech's net income of -$3.7M. Notably, Mustang Bio, Inc.'s price-to-earnings ratio is -- while AIM ImmunoTech's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Mustang Bio, Inc. is -- versus 13.27x for AIM ImmunoTech. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income MBIOMustang Bio, Inc.-- -- -- -$468K AIMAIM ImmunoTech13.27x -- $35K -$3.7M
-
Which has Higher Returns MBIO or ARMP?
Armata Pharmaceuticals, Inc. has a net margin of -- compared to Mustang Bio, Inc.'s net margin of -2301.55%. Mustang Bio, Inc.'s return on equity of -311.92% beat Armata Pharmaceuticals, Inc.'s return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital MBIOMustang Bio, Inc.-- -$0.08 $9.8M ARMPArmata Pharmaceuticals, Inc.68.08% -$0.74 $82.1M -
What do Analysts Say About MBIO or ARMP?
Mustang Bio, Inc. has a consensus price target of --, signalling upside risk potential of 8268.2%. On the other hand Armata Pharmaceuticals, Inc. has an analysts' consensus of $9.00 which suggests that it could grow by 52.54%. Given that Mustang Bio, Inc. has higher upside potential than Armata Pharmaceuticals, Inc., analysts believe Mustang Bio, Inc. is more attractive than Armata Pharmaceuticals, Inc..
Company Buy Ratings Hold Ratings Sell Ratings MBIOMustang Bio, Inc.0 0 0 ARMPArmata Pharmaceuticals, Inc.1 0 0 -
Is MBIO or ARMP More Risky?
Mustang Bio, Inc. has a beta of 2.086, which suggesting that the stock is 108.57% more volatile than S&P 500. In comparison Armata Pharmaceuticals, Inc. has a beta of 1.240, suggesting its more volatile than the S&P 500 by 23.97%.
-
Which is a Better Dividend Stock MBIO or ARMP?
Mustang Bio, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Armata Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Mustang Bio, Inc. pays -- of its earnings as a dividend. Armata Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios MBIO or ARMP?
Mustang Bio, Inc. quarterly revenues are --, which are smaller than Armata Pharmaceuticals, Inc. quarterly revenues of $1.2M. Mustang Bio, Inc.'s net income of -$468K is higher than Armata Pharmaceuticals, Inc.'s net income of -$26.7M. Notably, Mustang Bio, Inc.'s price-to-earnings ratio is -- while Armata Pharmaceuticals, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Mustang Bio, Inc. is -- versus 48.94x for Armata Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income MBIOMustang Bio, Inc.-- -- -- -$468K ARMPArmata Pharmaceuticals, Inc.48.94x -- $1.2M -$26.7M
-
Which has Higher Returns MBIO or CRIS?
Curis, Inc. has a net margin of -- compared to Mustang Bio, Inc.'s net margin of -243.36%. Mustang Bio, Inc.'s return on equity of -311.92% beat Curis, Inc.'s return on equity of -461.34%.
Company Gross Margin Earnings Per Share Invested Capital MBIOMustang Bio, Inc.-- -$0.08 $9.8M CRISCuris, Inc.98.52% -$0.49 $15.9M -
What do Analysts Say About MBIO or CRIS?
Mustang Bio, Inc. has a consensus price target of --, signalling upside risk potential of 8268.2%. On the other hand Curis, Inc. has an analysts' consensus of $14.00 which suggests that it could grow by 1106.9%. Given that Mustang Bio, Inc. has higher upside potential than Curis, Inc., analysts believe Mustang Bio, Inc. is more attractive than Curis, Inc..
Company Buy Ratings Hold Ratings Sell Ratings MBIOMustang Bio, Inc.0 0 0 CRISCuris, Inc.4 0 0 -
Is MBIO or CRIS More Risky?
Mustang Bio, Inc. has a beta of 2.086, which suggesting that the stock is 108.57% more volatile than S&P 500. In comparison Curis, Inc. has a beta of 4.025, suggesting its more volatile than the S&P 500 by 302.512%.
-
Which is a Better Dividend Stock MBIO or CRIS?
Mustang Bio, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Curis, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Mustang Bio, Inc. pays -- of its earnings as a dividend. Curis, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios MBIO or CRIS?
Mustang Bio, Inc. quarterly revenues are --, which are smaller than Curis, Inc. quarterly revenues of $3.2M. Mustang Bio, Inc.'s net income of -$468K is higher than Curis, Inc.'s net income of -$7.7M. Notably, Mustang Bio, Inc.'s price-to-earnings ratio is -- while Curis, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Mustang Bio, Inc. is -- versus 1.11x for Curis, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income MBIOMustang Bio, Inc.-- -- -- -$468K CRISCuris, Inc.1.11x -- $3.2M -$7.7M
-
Which has Higher Returns MBIO or PLX?
Protalix Biotherapeutics, Inc. has a net margin of -- compared to Mustang Bio, Inc.'s net margin of 13.19%. Mustang Bio, Inc.'s return on equity of -311.92% beat Protalix Biotherapeutics, Inc.'s return on equity of 12.06%.
Company Gross Margin Earnings Per Share Invested Capital MBIOMustang Bio, Inc.-- -$0.08 $9.8M PLXProtalix Biotherapeutics, Inc.53.37% $0.03 $61.1M -
What do Analysts Say About MBIO or PLX?
Mustang Bio, Inc. has a consensus price target of --, signalling upside risk potential of 8268.2%. On the other hand Protalix Biotherapeutics, Inc. has an analysts' consensus of $11.00 which suggests that it could grow by 514.53%. Given that Mustang Bio, Inc. has higher upside potential than Protalix Biotherapeutics, Inc., analysts believe Mustang Bio, Inc. is more attractive than Protalix Biotherapeutics, Inc..
Company Buy Ratings Hold Ratings Sell Ratings MBIOMustang Bio, Inc.0 0 0 PLXProtalix Biotherapeutics, Inc.1 0 0 -
Is MBIO or PLX More Risky?
Mustang Bio, Inc. has a beta of 2.086, which suggesting that the stock is 108.57% more volatile than S&P 500. In comparison Protalix Biotherapeutics, Inc. has a beta of -0.248, suggesting its less volatile than the S&P 500 by 124.798%.
-
Which is a Better Dividend Stock MBIO or PLX?
Mustang Bio, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Protalix Biotherapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Mustang Bio, Inc. pays -- of its earnings as a dividend. Protalix Biotherapeutics, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios MBIO or PLX?
Mustang Bio, Inc. quarterly revenues are --, which are smaller than Protalix Biotherapeutics, Inc. quarterly revenues of $17.9M. Mustang Bio, Inc.'s net income of -$468K is lower than Protalix Biotherapeutics, Inc.'s net income of $2.4M. Notably, Mustang Bio, Inc.'s price-to-earnings ratio is -- while Protalix Biotherapeutics, Inc.'s PE ratio is 25.76x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Mustang Bio, Inc. is -- versus 2.28x for Protalix Biotherapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income MBIOMustang Bio, Inc.-- -- -- -$468K PLXProtalix Biotherapeutics, Inc.2.28x 25.76x $17.9M $2.4M
Related Companies
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is IONQ The Best Quantum Stock to Buy?
Riding a wave of investor enthusiasm for the technology, quantum…
Is JetBlue The Best Airline Stock?
Following a general trend of improvement among airline stocks, shares…
Stock Ideas
Sell
47
Is NVDA Stock a Buy?
Market Cap: $4.3T
P/E Ratio: 60x
Buy
58
Is AAPL Stock a Buy?
Market Cap: $4.1T
P/E Ratio: 37x
Buy
73
Is GOOG Stock a Buy?
Market Cap: $3.7T
P/E Ratio: 39x
Alerts
Buy
80
FEIM alert for Dec 15
Frequency Electronics, Inc. [FEIM] is down 7.6% over the past day.
Buy
57
MOD alert for Dec 15
Modine Manufacturing Co. [MOD] is up 1.4% over the past day.
Sell
42
OKLO alert for Dec 15
Oklo, Inc. [OKLO] is down 4.82% over the past day.
